News Release
NEW YORK, Aug 13, 2009 (BUSINESS WIRE) -- Medidata Solutions (Nasdaq: MDSO), a leading global provider of hosted clinical development solutions, today announced its financial results for the second quarter ended June 30, 2009.
Net revenues for the second quarter of 2009 were $34.0 million, an increase of $8.3 million, or 32%, compared with $25.7 million in the second quarter of 2008. The increase in revenues was primarily due to a $6.4 million, or 36%, increase in revenues from application services, and a $1.8 million, or 24%, increase in revenues from professional services.
"Medidata executed well in the second quarter and first half year, posting strong results, while successfully completing its initial public offering. We continued to solidify our position as a market leader by expanding our global list of customers and partners, significantly enhancing our financial resources and building upon our strong growth trajectory," said Tarek Sherif, chairman and chief executive officer of Medidata Solutions. "Our customers increasingly look to us to help them achieve improved operational efficiency and productivity on a global scale in their drug development efforts. With our leading-edge technology, strong service orientation, and the vision and resources to execute, we are well-positioned to help our customers achieve their objectives, while driving our long-term growth."
Non-GAAP operating income* for the second quarter of 2009 was $4.3 million, compared with a loss of $2.5 million in the second quarter of 2008. Non-GAAP net income for the second quarter of 2009 was $1.6 million, or $0.09 per diluted share, compared with a loss of $4.7 million, or $0.70 per diluted share, in the second quarter of 2008.
For the second quarter of 2009, GAAP operating income was $0.8 million, compared with a loss of $5.5 million in the second quarter of 2008. GAAP net income for the period was $0.2 million, or $0.01 per diluted share, compared with a loss of $5.9 million, or $0.87 per diluted share, in the second quarter of 2008.
"As a private company for nearly a decade, we have focused on building quality solutions for our customers, a global sales and services presence and, more recently, a robust public company infrastructure. Now that the majority of this scalable infrastructure is in place, we are focused on profitable growth," commented Bruce Dalziel, chief financial officer.
Total cash and cash equivalents were $93.8 million at the end of the second quarter. The company received approximately $82.0 million in proceeds from its initial public offering, net of underwriting discounts and commissions, during the second quarter. The total outstanding principal balance of long-term debt at the end of the quarter was $14.3 million. Year to date, the company generated $12.1 million in cash flows from operations.
Second Quarter and Year-to-Date Business Highlights
- On June 24, 2009, Medidata Solutions priced its initial public offering at $14.00 a common share. The company began trading on the NASDAQ Global Market under the ticker symbol "MDSO" on June 25, 2009.
- Medidata's customer base and product usage continued to expand during the first and second quarter of 2009 across its product line and throughout the world. New customers included Kitasato University Research Center for Clinical Pharmacology, NiTi Surgical Solutions, PhotoCure ASA and PTC Therapeutics, Inc. Building on successful initial studies with Medidata Rave®, customers such as Galderma Pharma SA, Shionogi & Co, Ltd. and ImClone Systems Corp., an operating subsidiary of Eli Lilly, also expanded their arrangements with Medidata through new multiple-study contracts.
- The company's ASPire to Win® CRO partner program continued to expand during the quarter, with a total of three new partners joining in the first half of 2009: BLC Pro, Inc., Brightech International LLC and Sumisho Computer Systems Corporation. Medidata also added the Asian divisions of two existing global CRO partners earlier in the year, including EPS International (China) Co., Ltd. Globally, Medidata now has 20 partners in its ASPire to Win program.
- The company introduced the Medidata Technology Partner Program, which advances customers' trial capabilities by recognizing partners that have leveraged interoperability and data sharing with Medidata. Through this program, as well as the development of integration tools such as a standards and web-based API and Developer Central, an on-line community, Medidata has been advancing a best-of-breed approach to building eClinical suites. Current technology partners include eDiary vendors invivodata, PHT and CRF Health; IVR/IWR providers Almac and UBC; and SAS Drug Development analysis and reporting solution.
- Medidata introduced an extension of the Medidata Rave platform with Medidata Rave Monitor, which provides customers with new functionality to monitor investigator sites, a critical and costly function for research sponsors.
- CIO magazine honored two of Medidata's customers, Wyeth Research and Array BioPharma, with CIO 100 awards for their creative and cutting-edge use of technology to generate business value in projects leveraging Medidata Rave.
Financial Outlook
The following statements are based on current expectations and the company assumes no obligation to update or confirm them. These statements are forward-looking and inherently uncertain. Actual results may differ materially as a result of the factors identified below and the factors identified in our public filings made with the Securities and Exchange Commission, or other factors.
For the third quarter of 2009, the company expects revenues to be between $33 and $34 million. The company expects non-GAAP operating income to be between $3.4 and $4.4 million. Based on current estimates this would equate to a GAAP operating loss of $1.0 and $0.0 million. Non-GAAP net income is expected to be between $0.2 and $1.2 million. Based on current estimates this would equate to a GAAP net loss of between $1.7 and $0.7 million.
For the full year 2009, the company expects revenues to be between $135 and $137 million. Non-GAAP operating income is expected to be between $18.0 and $20.0 million. Based on current estimates this would equate to GAAP operating income between $2.0 and $4.0 million. Non-GAAP net income is expected to be between $6.5 and $8.5 million. Based on current estimates this would equate to GAAP net income between $0.0 and $2.0 million.
Total remaining backlog for 2009 was $62.9 million at the end of the second quarter. Remaining year backlog represents the amount of contractual revenue already booked which is expected to be recognized during the remainder of the year.
While changes in the stock price could change the fully diluted share count, for modeling purposes the company is assuming 23.6 million and 20.5 million fully diluted shares in the third quarter and full year, respectively.
Conclusion
Sherif noted in conclusion, "Medidata continues to build momentum in the marketplace, executing against our vision in what is a very dynamic environment. We are excited that our role as a leader and innovator in our industry allows us to increasingly help our customers meet their objectives, by developing and combining best of breed technologies in a fully integrated solution that is viewed as a key component of the evolving clinical development landscape."
Conference Call
The company plans to host its investor conference call today at 5:00 p.m. EDT to discuss its financial results for the second quarter 2009 and its outlook for the third quarter and full year 2009. The investor conference call will be available via live webcast on the "Investor" section of Medidata's Web Site at http://investor.mdsol.com. To participate by telephone, domestic participants may dial 877.874.1570 and international participants may dial 719.325.4933. Those interested in participating in the conference call should dial in at least 10 minutes prior to the call to register. Participants can also join the call via a simultaneous live audio webcast, which will be made available on the "Investor" section of Medidata's Web site at http://investor.mdsol.com. A replay of the conference call will be accessible until Thursday, August 27, 2009 by dialing 888.203.1112 domestically or 719.457.0820 internationally, and using passcode 6046830. An archive of the call will also be hosted on the "Investor" section of Medidata's Web site at http://investor.mdsol.com for a limited period of time.
About Medidata Solutions Worldwide
Medidata Solutions (www.mdsol.com) is a leading global provider of hosted clinical development solutions that enhance the efficiency of customers' clinical development processes and optimize their research and development investments. Medidata products and services allow customers to achieve clinical results more efficiently and effectively by streamlining the design, planning and management of key aspects of the clinical development process, including protocol development (Medidata Designer™), investigator benchmarking and budgeting (Medidata Grants Manager™), contract research organization (CRO) benchmarking and budgeting (Medidata CRO Contractor™), and the capture, management, analysis and reporting of clinical trial data (Medidata Rave®). Medidata's diverse customer base spans pharmaceutical, biotechnology and medical device companies, academic institutions, CROs and other research organizations, and includes more than 20 of the top 25 global pharmaceutical companies.
Cautionary Statement
Certain statements made in this press release are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 that involve significant risks and uncertainties about Medidata Solutions, Inc. ("Medidata"), including but not limited to statements about Medidata's products and services, business model, strategy and growth opportunities, profitability and competitive position. Forward-looking statements describe future expectations, plans, results or strategies and are generally preceded by words such as "future," "plan" or "planned," "will" or "should," "expected," "anticipates," "possible," "projected" or "targeted." You are cautioned that such statements should not be read as a guarantee of future performance or results, and will not necessarily be accurate indications of the times at, or by which, such performance or results will have been achieved. Such statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in these statements. Important factors that could cause such differences include, but are not limited to, those discussed in the "Risk Factors" section of Medidata's prospectus, such as (i) Medidata's ability to retain and expand its customer base, (ii) Medidata's ability to develop innovative products, (iii) the financial condition of Medidata's current and potential customers, (iv) changes in the regulatory environment and (v) general economic factors. You should consider these factors in evaluating the forward-looking statements included in this press release and not place undue reliance on such statements. The forward-looking statements are made as of the date hereof, and Medidata undertakes no obligation to update such statements as a result of new information, future events or otherwise.
*Non-GAAP Financial Information
Medidata Solutions provides Non-GAAP operating income, net income, and net income per share applicable to common stockholders data as additional information for its operating results. These measures are not in accordance with, or an alternative for, generally accepted accounting principles and may be different from Non-GAAP measures used by other companies. Medidata Solutions management believes these non-GAAP measures are useful to investors because this supplemental information facilitates comparisons to prior periods. Management uses these Non-GAAP measures to evaluate its financial results, develop budgets and manage expenditures. Investors are encouraged to review the reconciliations of these Non-GAAP financial measures to the comparable GAAP results, which are attached to this press release. Non-GAAP operating income excludes the impact of depreciation, amortization of intangible assets associated with acquisitions and stock-based compensation expense.Non-GAAP net income excludes the impact of amortization of intangible assets associated with acquisitions and stock-based compensation expense.
| MEDIDATA SOLUTIONS, INC. | |||||||||||||||||||
| CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) | |||||||||||||||||||
| (Amounts in thousands, except per share data) | |||||||||||||||||||
|
Three Months Ended |
Six Months Ended |
||||||||||||||||||
| 2009 | 2008 | 2009 | 2008 | ||||||||||||||||
| Revenues | |||||||||||||||||||
| Application services | $ | 24,523 | $ | 18,076 | $ | 48,188 | $ | 32,897 | |||||||||||
| Professional services | 9,505 | 7,677 | 19,442 | 13,835 | |||||||||||||||
| Total revenues | 34,028 | 25,753 | 67,630 | 46,732 | |||||||||||||||
| Cost of revenues | |||||||||||||||||||
| Application services | 5,845 | 4,889 | 11,515 | 9,364 | |||||||||||||||
| Professional services | 6,839 | 8,257 | 13,452 | 16,451 | |||||||||||||||
| Total cost of revenues | 12,684 | 13,146 | 24,967 | 25,815 | |||||||||||||||
| Gross profit | 21,344 | 12,607 | 42,663 | 20,917 | |||||||||||||||
| OPERATING COSTS AND EXPENSES: | |||||||||||||||||||
| Research and development | 5,789 | 4,778 | 11,286 | 9,650 | |||||||||||||||
| Sales and marketing | 6,745 | 6,173 | 13,458 | 11,636 | |||||||||||||||
| General and administrative | 8,037 | 7,144 | 14,858 | 12,951 | |||||||||||||||
| Total operating costs and expenses | 20,571 | 18,095 | 39,602 | 34,237 | |||||||||||||||
| OPERATING INCOME (LOSS) | 773 | (5,488 | ) | 3,061 | (13,320 | ) | |||||||||||||
| INTEREST AND OTHER EXPENSE (INCOME): | |||||||||||||||||||
| Interest expense | 405 | 492 | 839 | 1,092 | |||||||||||||||
| Interest income | (36 | ) | (30 | ) | (63 | ) | (66 | ) | |||||||||||
| Other expense (income), net | 3 | (215 | ) | 8 | (216 | ) | |||||||||||||
| Total interest and other expense, net | 372 | 247 | 784 | 810 | |||||||||||||||
| INCOME (LOSS) BEFORE INCOME TAXES | 401 | (5,735 | ) | 2,277 | (14,130 | ) | |||||||||||||
| PROVISION FOR INCOME TAXES | 201 | 169 | 383 | 334 | |||||||||||||||
| NET INCOME (LOSS) | $ | 200 | $ | (5,904 | ) | $ | 1,894 | $ | (14,464 | ) | |||||||||
| EARNINGS (LOSS) PER SHARE: | |||||||||||||||||||
| Basic | $ | 0.01 | $ | (0.87 | ) | $ | 0.23 | $ | (2.23 | ) | |||||||||
| Diluted | $ | 0.01 | $ | (0.87 | ) | $ | 0.11 | $ | (2.23 | ) | |||||||||
| WEIGHTED AVERAGE COMMON SHARES OUTSTANDING: | |||||||||||||||||||
| Basic | 7,385 | 6,952 | 7,212 | 6,585 | |||||||||||||||
| Diluted (1) | 17,769 | 6,952 | 17,596 | 6,585 | |||||||||||||||
| (1) Diluted shares outstanding on June 30, 2009 were 17,769,446, as compared to 6,951,876 in the second quarter of 2008. The change is a result of common stock equivalents which were excluded from the calculation of dilutive loss per share in prior year since the effects are anti-dilutive. | |||||||||||||||||||
| MEDIDATA SOLUTIONS, INC. | ||||||||||||||||||||||
| Reconciliation of GAAP Operating Income and GAAP Net Income to
Non-GAAP Operating Income and Non-GAAP Net Income (unaudited) (Amounts in thousands, except per share data) |
||||||||||||||||||||||
| Three Months Ended
June 30, |
Six Months Ended
June 30, |
|||||||||||||||||||||
| 2009 | 2008 | 2009 | 2008 | |||||||||||||||||||
| OPERATING INCOME (LOSS) : | ||||||||||||||||||||||
| GAAP operating income (loss) | $ | 773 | $ | (5,488 | ) | $ | 3,061 | $ | (13,320 | ) | ||||||||||||
| GAAP operating margins | 2.3 | % | (21.4 | )% | 4.5 | % | (28.4 | )% | ||||||||||||||
| Depreciation and amortization | 2,591 | 2,274 | 5,141 | 4,069 | ||||||||||||||||||
| Stock-based compensation | 920 | 764 | 1,923 | 1,365 | ||||||||||||||||||
| Non-GAAP operating income (loss) | $ | 4,284 | $ | (2,450 | ) | $ | 10,125 | $ | (7,886 | ) | ||||||||||||
| Non-GAAP operating margins | 12.6 | % | (9.5 | )% | 15.0 | % | (16.9 | )% | ||||||||||||||
| NET INCOME (LOSS): | ||||||||||||||||||||||
| GAAP net income (loss) | $ | 200 | $ | (5,904 | ) | $ | 1,894 | $ | (14,464 | ) | ||||||||||||
| Amortization | 457 | 406 | 913 | 474 | ||||||||||||||||||
| Stock-based compensation | 920 | 764 | 1,923 | 1,365 | ||||||||||||||||||
| Non-GAAP net income (loss) | $ | 1,577 | $ | (4,734 | ) | $ | 4,730 | $ | (12,625 | ) | ||||||||||||
| GAAP basic earnings (loss) per share | $ | 0.01 | $ | (0.87 | ) | $ | 0.23 | $ | (2.23 | ) | ||||||||||||
| GAAP diluted earnings (loss) per share | $ | 0.01 | $ | (0.87 | ) | $ | 0.11 | $ | (2.23 | ) | ||||||||||||
| Non-GAAP basic earnings (loss) per share | $ | 0.20 | $ | (0.70 | ) | $ | 0.62 | $ | (1.96 | ) | ||||||||||||
| Non-GAAP diluted earnings (loss) per share | $ | 0.09 | $ | (0.70 | ) | $ | 0.27 | $ | (1.96 | ) | ||||||||||||
The table above presents a reconciliation of GAAP to non-GAAP operating income, net income and net income per share applicable to common stockholders for the three months and six months ended June 30, 2009 and 2008. Non-GAAP operating income excludes the impact of depreciation, amortization of intangible assets associated with acquisitions and stock-based compensation expense.Non-GAAP net income excludes the impact of amortization of intangible assets associated with acquisitions and stock-based compensation expense.
| MEDIDATA SOLUTIONS, INC. | |||||||||
| CONDENSED CONSOLIDATED BALANCE SHEET | |||||||||
| (Amounts in thousands, except per share data) | |||||||||
| June 30,
2009 |
December 31,
2008 |
||||||||
| (unaudited) | |||||||||
| ASSETS | |||||||||
| CURRENT ASSETS: | |||||||||
| Cash and cash equivalents | $ | 93,763 | $ | 9,784 | |||||
| Accounts receivable, net of allowance for doubtful accounts of | |||||||||
| $364 and $309, respectively | 21,249 | 25,198 | |||||||
| Prepaid commission expense | 3,566 | 3,330 | |||||||
| Prepaid expenses and other current assets | 3,164 | 5,950 | |||||||
| Deferred income taxes | 303 | 303 | |||||||
| Total current assets | 122,045 | 44,565 | |||||||
|
Restricted Cash |
532 | 545 | |||||||
| Furniture, fixtures and equipment, net | 12,937 | 13,599 | |||||||
| Goodwill | 9,799 | 9,799 | |||||||
| Intangible assets, net | 5,316 | 6,230 | |||||||
| Other assets | 479 | 452 | |||||||
| TOTAL ASSETS | $ | 151,108 | $ | 75,190 | |||||
| LIABILITIES AND STOCKHOLDERS' EQUITY | |||||||||
| CURRENT LIABILITIES: | |||||||||
| Accounts payable | $ | 1,768 | $ | 3,316 | |||||
| Accrued payroll and other compensation | 6,825 | 7,902 | |||||||
| Accrued expenses and other | 5,256 | 3,469 | |||||||
| Deferred revenue | 74,462 | 69,834 | |||||||
| Capital lease obligations | 4,157 | 4,388 | |||||||
| Current portion of debt obligation | 1,500 | 1,500 | |||||||
| Total current liabilities | 93,968 | 90,409 | |||||||
| NONCURRENT LIABILITIES: | |||||||||
| Deferred revenue, less current portion | 28,337 | 31,787 | |||||||
| Capital lease obligations, less current portion | 1,566 | 2,672 | |||||||
| Long-term debt | 12,183 | 12,866 | |||||||
| Other long-term liabilities | 675 | 611 | |||||||
| Total noncurrent liabilities | 42,761 | 47,936 | |||||||
| Total liabilities | 136,729 | 138,345 | |||||||
| CONVERTIBLE REDEEMABLE PREFERRED STOCK: | |||||||||
| Series B, par value $0.01 per share; None authorized, issued and outstanding | |||||||||
| at June 30, 2009; 1,336 shares authorized, issued and outstanding, | |||||||||
| and liquidation value of $1,101 at December 31, 2008 | - | 1,099 | |||||||
| Series C, par value $0.01 per share; None authorized, issued and outstanding | |||||||||
| at June 30, 2009; 181 shares authorized, issued and outstanding, | |||||||||
| and liquidation value of $181 at December 31, 2008 | - | 179 | |||||||
| Series D, par value $0.01 per share; None authorized, issued and outstanding | |||||||||
| at June 30, 2009; 2,752 shares authorized, issued and outstanding, | |||||||||
| and liquidation value of $12,088 at December 31, 2008 | - | 11,967 | |||||||
| COMMITMENTS AND CONTINGENCIES | |||||||||
| STOCKHOLDERS' EQUITY (DEFICIT): | |||||||||
| Convertible preferred stock, Series A, par value $0.01 per share; None authorized, | |||||||||
| issued and outstanding at June 30, 2009; 2,385 shares authorized, | |||||||||
| issued and outstanding, and liquidation value of $1,193 at December 31, 2008 | - | 24 | |||||||
| Common stock, par value $0.01 per share; 25,000 shares authorized, 22,648 shares | |||||||||
| issued and outstanding at June 30, 2009; 20,000 shares authorized, 7,532 shares | |||||||||
| issued and 7,035 shares outstanding at December 31, 2008 | 226 | 75 | |||||||
| Additional paid-in capital | 110,977 | 22,433 | |||||||
| Treasury stock, none and 497 shares, respectively | - | (6,000 | ) | ||||||
| Accumulated other comprehensive loss | (180 | ) | (389 | ) | |||||
| Accumulated deficit | (96,644 | ) | (92,543 | ) | |||||
| Total stockholders' equity (deficit) | 14,379 | (76,400 | ) | ||||||
| TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY | $ | 151,108 | $ | 75,190 | |||||
| MEDIDATA SOLUTIONS, INC. AND SUBSIDIARIES | ||||||||
| CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) | ||||||||
| (Amounts in thousands) | ||||||||
| Six Months Ended June 30, | ||||||||
| 2009 | 2008 | |||||||
| CASH FLOWS FROM OPERATING ACTIVITIES: | ||||||||
| Net income (loss) | $ | 1,894 | $ | (14,464 | ) | |||
| Adjustments to reconcile net income (loss) to net cash provided by | ||||||||
| operating activities: | ||||||||
| Depreciation and amortization | 5,141 | 4,069 | ||||||
| Stock-based compensation | 1,923 | 1,365 | ||||||
| Write-off of acquired research and development costs | - | 700 | ||||||
| Deferred income taxes | 28 | - | ||||||
| Amortization of debt issuance costs | 67 | 29 | ||||||
| Changes in operating assets and liabilities: | ||||||||
| Accounts receivable | 3,949 | (6,055 | ) | |||||
| Prepaid commission expense | (236 | ) | (742 | ) | ||||
| Prepaid expenses and other current assets | (470 | ) | 325 | |||||
| Other assets | (52 | ) | 13 | |||||
| Accounts payable | (905 | ) | (2,430 | ) | ||||
| Accrued payroll and other compensation | (1,077 | ) | 877 | |||||
| Accrued expenses and other | 661 | 1,770 | ||||||
| Deferred revenue | 1,178 | 19,949 | ||||||
| Other long-term liabilities | 36 | 83 | ||||||
| Net cash provided by operating activities | 12,137 | 5,489 | ||||||
| CASH FLOWS FROM INVESTING ACTIVITIES: | ||||||||
| Purchases of furniture, fixtures and equipment | (2,151 | ) | (2,176 | ) | ||||
| Decrease in restricted cash | 13 | - | ||||||
| Fast Track acquisition related costs | - | (625 | ) | |||||
| Cash and cash equivalents acquired through acquisition | - | 1,049 | ||||||
| Net cash used in investing activities | (2,138 | ) | (1,752 | ) | ||||
| CASH FLOWS FROM FINANCING ACTIVITIES: | ||||||||
| Proceeds from exercise of stock options | 3 | 7 | ||||||
| Repayment of obligations under capital leases | (2,486 | ) | (1,933 | ) | ||||
| Proceeds from initial public offering, net of underwriting discounts and commissions | 82,026 | - | ||||||
| Payment of costs associated with initial public offering | (2,563 | ) | (1,178 | ) | ||||
| Payment of preferred stock accumulated accrued dividends | (2,282 | ) | - | |||||
| Repayment of debt obligation | (750 | ) | - | |||||
| Net cash provided by (used in) financing activities | 73,948 | (3,104 | ) | |||||
| NET INCREASE IN CASH AND CASH EQUIVALENTS | 83,947 | 633 | ||||||
| EFFECT OF EXCHANGE RATE CHANGES ON CASH | ||||||||
| AND CASH EQUIVALENTS | 32 | 2 | ||||||
| CASH AND CASH EQUIVALENTS -- Beginning of period | 9,784 | 7,746 | ||||||
| CASH AND CASH EQUIVALENTS -- End of period | $ | 93,763 | $ | 8,381 | ||||
SOURCE: Medidata Solutions
Investor Contact:
Medidata Solutions
Hulus Alpay, 212-419-1025
halpay@mdsol.com
or
Media Contact:
Lois Paul & Partners
Melissa Zipin, 781-782-5726
melissa_zipin@lpp.com
Copyright Business Wire 2009